Table 2.
Correlation between BRCA status and systemic inflammatory markers
| BRCA wild type | BRCA mutated | p value | |
|---|---|---|---|
|
SII < 1000 |
62 (71.3) | 26 (65.0) | 0.536 |
| ≥ 1000 | 25 (28.7) | 14 (35.9) | |
|
NLR < 3 |
58 (66.7) | 21 (52.5) | 0.168 |
| ≥ 3 | 29 (33.3) | 19 (47.5) | |
|
PLR < 200 |
61 (70.1) | 25 (62.5) | 0.419 |
| ≥ 200 | 26 (29.9) | 15 (37.5) | |
|
ELR < 0.03 |
4 (4.6) | 4 (10.0) | 0.259 |
| ≥ 0.03 | 83 (95.4) | 36 (90.0) | |
|
ENL < 0.6 |
1 (1.1) | 2 (5.0) | 0.233 |
| ≥ 0.6 | 86 (98.9) | 38 (95.0) | |
|
FAR < 10 |
53 (60.9) | 23 (57.5) | 0.846 |
| ≥ 10 | 34 (39.1) | 17 (42.5) | |
|
MLR < 0.2 |
12 (13.8) | 9 (22.5) | 0.303 |
| ≥ 0.2 | 75 (86.2) | 31 (77.5) |
On 232 patients BRCA status unavailable
NLR neutrophil–lymphocyte ratio, PLR platelet-lymphocyte ratio, ELR eosinophil-lymphocyte ratio, MLR monocyte-lymphocyte ratio, systemic immune inflammation index (SII—platelet x neutrophil–lymphocyte ratio), ENL (eosinophil x neutrophil)/lymphocyte, FAR fibrinogen-albumin ratio